Additionally, XZF was effective in suppressing IFN-γ-induced PD-L1 expression in PC-3 and DU145 prostate cancer cells and inhibited the PD-L1/PD-1 interaction by 93% at a concentration of 200 μg/mL, closely matching the 98% inhibition achieved with atezolizumab. The gene discussed is PDCD1; the disease is prostate carcinoma.